SYK Quote, Financials, Valuation and Earnings

Baxter International has a net margin of 11.15% compared to Stryker's net margin of 4.8%. Stryker's return on equity of 14.2% beat Baxter International's return on equity of -7.38%.

Stryker has a consensus price target of $423.98, signalling upside risk potential of 11.31%. On the other hand Baxter International has an analysts' consensus of $38.68 which suggests that it could grow by 25.17%. Given that Baxter International has higher upside potential than Stryker, analysts believe Baxter International is more attractive than Stryker.

Stryker has a beta of 0.929, which suggesting that the stock is 7.091% less volatile than S&P 500. In comparison Baxter International has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.167%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.86%. Baxter International offers a yield of 2.98% to investors and pays a quarterly dividend of $0.17 per share. Stryker pays 40.73% of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.9B, which are larger than Baxter International quarterly revenues of $2.6B. Stryker's net income of $654M is higher than Baxter International's net income of $126M. Notably, Stryker's price-to-earnings ratio is 51.48x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.33x versus 1.33x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Becton Dickinson & has a net margin of 11.15% compared to Stryker's net margin of 5.84%. Stryker's return on equity of 14.2% beat Becton Dickinson &'s return on equity of 5.86%.

Stryker has a consensus price target of $423.98, signalling upside risk potential of 11.31%. On the other hand Becton Dickinson & has an analysts' consensus of $225.25 which suggests that it could grow by 34.7%. Given that Becton Dickinson & has higher upside potential than Stryker, analysts believe Becton Dickinson & is more attractive than Stryker.

Stryker has a beta of 0.929, which suggesting that the stock is 7.091% less volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.312, suggesting its less volatile than the S&P 500 by 68.788%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.86%. Becton Dickinson & offers a yield of 2.38% to investors and pays a quarterly dividend of $1.04 per share. Stryker pays 40.73% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.9B, which are larger than Becton Dickinson & quarterly revenues of $5.3B. Stryker's net income of $654M is higher than Becton Dickinson &'s net income of $308M. Notably, Stryker's price-to-earnings ratio is 51.48x while Becton Dickinson &'s PE ratio is 31.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.33x versus 2.32x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 11.15% compared to Stryker's net margin of 14.45%. Stryker's return on equity of 14.2% beat Boston Scientific's return on equity of 9.57%.

Stryker has a consensus price target of $423.98, signalling upside risk potential of 11.31%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 12.89%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

Stryker has a beta of 0.929, which suggesting that the stock is 7.091% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.86%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.9B, which are larger than Boston Scientific quarterly revenues of $4.7B. Stryker's net income of $654M is lower than Boston Scientific's net income of $674M. Notably, Stryker's price-to-earnings ratio is 51.48x while Boston Scientific's PE ratio is 75.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.33x versus 8.72x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of 11.15% compared to Stryker's net margin of 30.99%. Stryker's return on equity of 14.2% beat Intuitive Surgical's return on equity of 15.82%.

Stryker has a consensus price target of $423.98, signalling upside risk potential of 11.31%. On the other hand Intuitive Surgical has an analysts' consensus of $573.63 which suggests that it could grow by 6.92%. Given that Stryker has higher upside potential than Intuitive Surgical, analysts believe Stryker is more attractive than Intuitive Surgical.

Stryker has a beta of 0.929, which suggesting that the stock is 7.091% less volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.

Stryker has a quarterly dividend of $0.84 per share corresponding to a yield of 0.86%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stryker pays 40.73% of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Stryker quarterly revenues are $5.9B, which are larger than Intuitive Surgical quarterly revenues of $2.3B. Stryker's net income of $654M is lower than Intuitive Surgical's net income of $698.4M. Notably, Stryker's price-to-earnings ratio is 51.48x while Intuitive Surgical's PE ratio is 78.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stryker is 6.33x versus 22.35x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.